[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Juan Jiao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635669","yishen-shujin-decoction-for-fibromyalgia-syndrome-100635669",false,"NCT07555691","Yishen Shujin Decoction for Fibromyalgia Syndrome","A Randomized Controlled Clinical Trial and Mechanistic Investigation of Yishen Shujin Decoction for Fibromyalgia Syndrome","Inclusion Criteria:\n\n* Patients with primary fibromyalgia who met the FM classification criteria established by the American College of Rheumatology in 2016.\n* TCM syndromes of liver qi stagnation and yin blood insufficiency, or hepatic and renal yin deficiency.\n* aged 18 years old and above, 75 years old and below.\n* pain VAS score ≥ 4.\n* not taking the treatment of FM drugs or not using the treatment of FM program for more than 1 month.\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Patients with severe depression or anxiety ;\n* patients with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases and thrombotic diseases ;\n* Lactating or pregnant women ;\n* patients with allergy to therapeutic ingredients ;\n* patients with severe pain caused by other diseases ( such as diabetic pain or postherpetic neuralgia ) ;\n* patients who have recently participated in clinical trials of the same indications ；\n* Patients who are male, right-handed, or have contraindications for MRI will not undergo MRI scanning.\n\nContraindications include:\n\nHistory of neurological diseases: brain tumor, stroke, epilepsy, traumatic brain injury, multiple sclerosis, etc.\n\nIncompatible implants: cardiac pacemaker, defibrillator, certain types of aneurysm clips, cochlear implants, neurostimulators, etc.\n\nPresence of metallic foreign bodies in the body: dentures, intraorbital metallic fragments, shrapnel in certain body regions, etc.\n\nClaustrophobia.","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This 24-week prospective study (12-week intervention + 12-week follow-up) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the therapeutic effects of YishenShujin Decoction, a clinically established herbal prescription, in patients with fibromyalgia (FM). The primary outcome is pain intensity measured by the Brief Pain Inventory (BPI). Secondary outcomes include improvements in the Fibromyalgia symptom scale(FS), revised Fibromyalgia Impact Questionnaire(FIQR), the Short Form-36 Health Status Questionnaire (SF-36), and FM-associated comorbidities. Safety profiles will be systematically monitored. In addition, brain structural and functional MRI will be used in this study to explore the underlying mechanisms.The findings aim to establish evidence for the formula's efficacy and provide insights into its role in FM management.",[27],"Fibromyalgia Syndrome",[29,30,31],"MRI","RCT","Chinese medicine","RECRUITING","2026-04-21",{"date":35,"type":36},"2026-04-29","ACTUAL",{"date":38,"type":36},"2025-03-01",{"date":40,"type":21},"2027-10-31",{"name":42,"class":43},"Juan Jiao","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100556626","effect-of-transcutaneous-auricular-electroacupuncture-on-sleep-disturbances-in-patients-with-rheumatoid-arthritis-a-randomized-double-blind-clinical-trial-100556626","NCT06527547","Effect of Transcutaneous Auricular Electroacupuncture on Sleep Disturbances in Patients With Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial","Inclusion Criteria:\n\n1. Meets the 2010 ACR\u002FEULAR criteria for rheumatoid arthritis.\n2. Poor sleep quality (PSQI score \\> 7).\n3. Disease activity is moderate to low or in remission (DAS28 score ≤ 5.1).\n4. No risk of sleep apnea (STOP-Bang questionnaire \\\u003C 3).\n5. Aged between 18 and 70.\n6. The type and dosage of rheumatoid arthritis medication must be stable for at least 4 weeks.\n7. Signed informed consent.\n\nExclusion Criteria:\n\n1. People with acute infectious diseases, whether generalized or localized;\n2. Those with severe internal organ diseases (such as coronary heart disease, arrhythmia, malignant tumors, renal failure, etc.);\n3. Those working night shifts during the intervention period;\n4. Those with other rheumatic diseases such as systemic lupus erythematosus, fibromyalgia, and Sjogren's syndrome;\n5. Those undergoing treatment with steroids, sleeping pills, antidepressants, or antipsychotics;\n6. Pregnant and breastfeeding women;\n7. Those who cannot tolerate transcutaneous auricular electrostimulation.","72 Years",{"count":53,"type":21},52,[24],"The purpose of this clinical trial is to determine whether transcutaneous auricular vagus nerve stimulation (taVNS) is suitable for improving sleep disorders in patients with rheumatoid arthritis (RA). It will also evaluate the safety of taVNS. The main questions it aims to answer are:\n\nCan taVNS improve the sleep quality of RA patients? What medical issues might RA patients experience while receiving taVNS treatment? Researchers will compare taVNS with a placebo (a similar substance that does not contain the actual treatment) to see if taVNS is effective in improving sleep disorders in RA patients.\n\nParticipants will:\n\nReceive taVNS or sham stimulation daily for 4 weeks Keep a daily sleep diary and visit the hospital once a week for check-ups and tests Record their sleep quality and related symptoms This study aims to provide a new, safe, and effective non-drug therapy for sleep disorders related to RA.",[57,58,59],"Transcutaneous Electric Nerve Stimulation","Rheumatoid Arthritis","Sleep Quality","2025-04-10",{"date":62,"type":36},"2025-04-13",{"date":64,"type":36},"2024-06-06",{"date":66,"type":21},"2025-12-31",{"name":42,"class":43},""]